MAIN LJUBLJANA SITE
REVIEW ABSTRACT SUBMISSION
GENERAL INFORMATION
PROGRAMME OVERVIEW
ONLINE COURSE EVALUATIONS
SYMPOSIA
FREE PAPERS
POSTERS
CORNEA DAY
LIVE SURGERY
YOUNG OPHTHALMOLOGISTS PROGRAMME
CATARACT SURGERY DIDACTIC COURSE
REFRACTIVE SURGERY DIDACTIC COURSE
BASIC OPTICS COURSE
CORNEA DIDACTIC COURSE
SLOVENIAN SOCIETY OF CATARACT & REFRACTIVE SURGEONS SYMPOSIUM
SURGICAL SKILLS TRAININGFirst Author: AliDirani LEBANON
Co Author(s): Ali Fadlallah Elias Chelala Hala El Rami George Cherfan Elias Jarade
Purpose:
To evaluate the safety and clinical outcome
of phakic Visian toric implantable collamer lens (ICL)
(STAAR Surgical, Monrovia, CA) insertion after corneal
collagen cross-linking (CXL) in progressive keratoconus.
Setting:
: Beirut Eye Specialist Hospital, Beirut, Lebanon
Methods:
A retrospective study examined the results
of the two-step CXL and Visian toric ICL implantation
in 16 eyes of 10 patients with keratoconus. The two
procedures were done at an interval of 6 months. Data
were collected preoperatively, at the 6-month follow-up
visit after CXL, and at the 6-month follow-up visit after
ICL implantation.
Results:
CXL induced a statistically signifi cant decrease
in steep keratometry (50.02 ± 4.07 at baseline
to 48.74 ± 4.05 at 6 months after CXL, P = .001) without
any signifi cant change in visual acuity or refraction. At
6-month follow-up after ICL implantation, mean K (max)
was 50.49 ± 4.07 versus 52.29 ± 4.79 D at baseline
(P = .001). Mean uncorrected distance visual acuity
improved from 1.67 ± 0.49 to 0.17 ± 0.06 logMAR
(P = .001) and mean corrected distance visual acuity
improved from 0.15 ± 0.06 to 0.12 ± 0.04 logMAR
(P = .023). Mean spherical equivalent decreased from
-7.24 ± 3.53 to -0.89 ± 0.76 D (P = .001) and mean
cylinder decreased from 2.64 ± 1.28 to 1.16 ± 0.64 D
(P = .001). The safety and effi cacy indices were 1.08 ±
0.13 and 0.97 ± 0.08, respectively. No intraoperative or
postoperative complications occurred.
Conclusions:
Implantation of the Visian toric ICL
following CXL is an effective option for improving visual
acuity in patients with keratoconus. FINANCIAL INTEREST: NONE